<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-633
Date of Submission: 2024-12-28

This report was submitted by a Other Healthcare Professional from Rhodes, Deleon and Blanchard Medical Center concerning patient ANON-PX-9079. The subject is a 42-year-old male with a significant medical history including hypertension, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 222mg, initiated on 2024-12-17 for Hypertension and discontinued on 2024-12-21.

On approximately 2024-12-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Dizziness, Stevens-Johnson syndrome. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed edge and advised focus. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed player and advised service. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Lead effect debate. Although author commercial share whether laugh. It use five defense.</data>
report_id: ADR-2024-633
report_date: '2024-12-28'
patient_details:
  patient_id: ANON-PX-9079
  gender: Male
  relevant_history:
  - hypertension
  - seasonal allergies
  age_at_reaction: 42
suspected_drugs:
- drug_name: Lisinopril
  dosage: 222mg
  route_of_administration: Oral
  start_date: '2024-12-17'
  indication_for_use: Hypertension
  drug_class: ACE inhibitor
  end_date: '2024-12-21'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2024-12-21'
  severity: Moderate
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed edge and advised focus.
- symptom_name: Dizziness
  onset_date: '2024-12-21'
  severity: Severe
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2024-12-21'
  severity: Moderate
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed player and advised service.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
reporting_facility: Rhodes, Deleon and Blanchard Medical Center
reporter_type: Other Healthcare Professional
notes: Lead effect debate. Although author commercial share whether laugh. It use
  five defense.
